GleamWall
中文EN

CTNM Contineum Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1855175 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.9%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.8%
ROA-28.3%
ROIC (approx.)-37.1%
Asset turnover—

Leverage & solvency

Liabilities / assets4.5%
Debt / equity0.00x
Current ratio31.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
R&D expense$51.52M$38.42M
SG&A expense$16.54M$12.47M
Operating income-$68.06M-$50.89M
Interest expense—$0
Pretax income-$60.14M-$42.26M
Income tax$0$0
Net income-$59.98M-$42.26M
EBITDA-$67.74M-$50.64M
EPS (basic)-2.17-2.18
EPS (diluted)-2.17-2.18
Weighted avg. shares (diluted)27.70M19.35M
Balance sheet
Cash & equivalents$75.60M$21.94M
Short-term investments$187.29M$182.82M
Current assets$267.92M$206.39M
PP&E, net$830,000$989,000
Total assets$276.64M$212.85M
Current liabilities$9.74M$9.97M
Total liabilities$15.65M$14.78M
Shareholders' equity$260.99M$198.07M
Cash flow statement
Operating cash flow-$55.31M-$32.84M
Capital expenditure$231,000$514,000
Free cash flow-$55.54M-$33.36M
Investing cash flow-$3.71M-$69.74M
Financing cash flow$112.69M$109.00M
Depreciation & amortization$323,000$258,000
Stock-based compensation$10.04M$6.80M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.